.jpg?w=340&itok=zEEps9JU "IPT discussed in technical publications."){kind=icon}
In a fast-moving market like healthcare, speed matters. Metys®, from Symphony Health, an ICON plc company, delivers weekly insights up to 3 days faster than other platforms – so you can respond to competitive shifts wi...
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Supporting reimbursement decisions with data from external control arms
Data is at the heart of every decision made by CROs, and so can have significant legal and financial implications. In this article ICON experts weigh in on maximising the efficacy of data and ensuring the scientific rigour HTAs expect.
This article is taken from European Pharmaceutical Contractor, August 2022, pages 52-55. Samedan Ltd
-
Pharmacovigilance outsourcing: Ensuring a positive experience
Karen Johnstone and Sabine Richter discuss current outsourcing practices and tips for selecting a service provider to ensure a successful relationship.
-
Will big tech dominate healthcare in the years ahead?
Louisa Roberts, VP of Corporate Development and Partnerships, considers the benefits of partnerships with tech companies.
-
The ecosystem overtakes the producers in pharma and life sciences
This article discusses the substantial number of significant acquisitions and mergers in the pharma and life sciences industry, and features ICON’s $12bn acquisition of PRA Health Sciences back in February.
-
The central role of Interactive Response Technology in today's clinical trials
Michelle Lynskey, Global Head of Interactive Response Technology and Clinical Supplies Management, offers her insights on the role of IRT in clinical trials (pages 42-43).
-
How COVID-19 has changed pharmacovigilance
Dr Andrew Garrett contributes to this article in Pharmafocus: How COVID-19 has changed pharmacovigilance. The article explores how drug safety can be ensured while numerous vaccines and treatments come to market in record time to deal with COVID-19.
-
.jpg?w=545&itok=QdJ1wxEM "IPT discussed in technical publications.")
Data capture in a post-digital clinical trial landscape
A thought leadership article authored by Tom O’Leary on how collected data from digital health technologies, coupled with novel clinical trial models, have the ability to increase the value proposition of drugs and medical devices.
This article is taken from Innovations in Pharmaceutical Technology Autumn/Winter 2020, pages 38-40. © Samedan Ltd
-
BARDA reselects ICON as preferred partner
An article focused on the BARDA announcement that ICON continues to be a part of The Clinical Trials Planning and Execution component of the CSN, responsible for planning and executing clinical studies to support medical countermeasure development.
-
The importance of partnering for bioanalytical studies
BioPharm International speaks with ICON's Robert Kernstock about the need for bioanalytical testing programs and regulatory strategies for potential new biologics.
-
Role of data in revolutionising the CRO industry
In a wide-ranging interview with PharmaBoardroom, ICON CIO, Tom O’Leary highlights the role of data in revolutionising the CRO industry and the steps that still need to be taken to better match patients with targeted therapies and improve health outcomes.
